FY25 revenue and test volumes declined due to Medicare non-coverage, but AUA guideline inclusion and APAC growth offer future upside. Cash burn remains high, with capital focused on evidence generation and product innovation.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.